

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
PHASE III CLINICAL TRIAL OF 13-VALENT PNEUMOCOCCAL
CONJUGATE VACCINE IS NEAR COMPLETION AND STATISTICAL
UNBLINDING WILL COMMENCE SOON

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The Phase III clinical trial of the Group’s 13-valent pneumococcal conjugate vaccine candidate was initiated in February 2022 at five sites in the Yunnan Province, including Lincang and Dali, with a total of 3,780 subjects enrolled. The Phase III clinical trial is currently at the stage of collecting blood samples 6 months after the full course of vaccination of the enrolled subjects. To date, the basic immunization MOPA serology testing has been completed. The clinical trial will soon proceed to statistical unblinding work.

The Phase I clinical trial of the 13-valent pneumococcal conjugate vaccine was initiated in February 2021 at the Centre for Disease Control and Prevention of Liucheng County, Guangxi Province, and the enrollment of all 200 subjects aged two months to 59 weeks was completed in June 2021. The results of the completed Phase I clinical trial to date have demonstrated good safety profile and immunogenicity of the vaccine.

The 13-valent pneumococcal conjugate vaccine is used for the prevention of diseases associated with infections caused by the 13 pneumococcal serotypes included in this vaccine (Types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). The Group has completed the construction of the production workshops for this vaccine with a designed manufacturing capacity of 30 million doses.

The 13-valent pneumococcal conjugate vaccine is one of the best-selling vaccine varieties in the world. According to Pfizer's 2022 annual report, Pfizer's global sales of the pneumococcal conjugate vaccine in the year of 2022 was approximately USD6,337 million.

By order of the Board
AIM Vaccine Co., Ltd.

Mr. Yan ZHOU

*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, October 17, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.